ArticlePloS one2013
Promotion of prescription drugs to consumers and providers, 2001-2010.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- The Effect of Including Quantitative Information on Multiple Endpoints in Direct-to-Consumer Prescription Drug Television Advertisements.Medical decision making : an international journal of the Society for Medical Decision Making · 2019Trial
- Are Disease Awareness Links on Prescription Drug Websites Misleading? A Randomized Study.Journal of health communication · 2016Trial
- Inequitable Distribution of Global Economic Benefits from Pneumococcal Conjugate Vaccination.Vaccines · 2024Article
- Pharmaceutical Drug Promotion and Rational Drug Use: Assessment of Healthcare Workers Perspective.Integrated pharmacy research & practice · 2024Article
- Article
- Financial Conflicts of Interest in Propensity Score-Matched Studies Evaluating Biologics and Biosimilars for Inflammatory Bowel Disease.Journal of the Canadian Association of Gastroenterology · 2022Article
- Article
- Conflicts of Interest in Inflammatory Bowel Disease Articles on UpToDate.Journal of the Canadian Association of Gastroenterology · 2021Article
- The patent buyout price for human papilloma virus (HPV) vaccine and the ratio of R&D costs to the patent value.PloS one · 2021Article
- Critical Evaluation of Drug Advertisements in a Medical College in Lalitpur, Nepal.Journal of multidisciplinary healthcare · 2020Article
- Polypharmacy: a healthcare conundrum with a pharmacogenetic solution.Critical reviews in clinical laboratory sciences · 2019Article
- Medicines Information and the Regulation of the Promotion of Pharmaceuticals.Science and engineering ethics · 2019Article
- Communicating Risk Information in Direct-to-Consumer Prescription Drug Television Ads: A Content Analysis.Health communication · 2019Article
- Article
- Prevalence of Financial Conflicts of Interest Among Authors of Clinical Guidelines Related to High-Revenue Medications.JAMA internal medicine · 2018Article
- Disclosing accelerated approval on direct-to-consumer prescription drug websites.Pharmacoepidemiology and drug safety · 2018Article
- Impact of New Medications and $4 Generic Programs on Overactive Bladder Treatment Among Older Adults in the United States, 2000-2015.Medical care · 2018Article
- Testimonials and Informational Videos on Branded Prescription Drug Websites: Experimental Study to Assess Influence on Consumer Knowledge and Perceptions.Journal of medical Internet research · 2018Article
- Effect of Direct-to-Consumer Advertising on Statin Use in the United States.Medical care · 2017Article
- Effect of Prescription Drug Coupons on Statin Utilization and Expenditures: A Retrospective Cohort Study.Pharmacotherapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPharmaceutical firms heavily promote their products and may have changed marketing strategies in response to reductions in new product approvals, restrictions on some forms of promotion, and the expanding role of biologic therapies.
methodsWe used descriptive analyses of annual cross-sectional data from 2001 through 2010 to examine direct-to-consumer advertising (DTCA) (Kantar Media) and provider-targeted promotion (IMS Health and SDI), including: (1) inflation-adjusted total promotion spending ($ and percent of sales); (2) distribution by channel (consumer v. provider); and (3) provider specialty both for the industry as a whole and for top-selling biologic and small molecule therapies.
resultsTotal promotion peaked in 2004 at US$36.1 billion (13.4% of sales). By 2010 it had declined to $27.7B (9.0% of sales). Between 2006 and 2010, similar declines were seen for promotion to providers and DTCA (both by 25%). DTCA's share of total promotion increased from 12% in 2002 to 18% in 2006, but then declined to 16% and remains highly concentrated. Number of products promoted to providers peaked in 2004 at over 3000, and then declined 20% by 2010. In contrast to top-selling small molecule therapies having an average of $370 million (8.8% of sales) spent on promotion, top biologics were promoted less, with only $33 million (1.4% of sales) spent per product. Little change occurred in the composition of promotion between primary care physicians and specialists from 2001-2010.
conclusionsThese findings suggest that pharmaceutical companies have reduced promotion following changes in the pharmaceutical pipeline and patent expiry for several blockbuster drugs. Promotional strategies for biologic drugs differ substantially from small molecule therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.